Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CUE |
---|---|---|
09:32 ET | 10659 | 1.6 |
09:34 ET | 500 | 1.6 |
09:36 ET | 956 | 1.6 |
09:38 ET | 100 | 1.61 |
09:41 ET | 100 | 1.61 |
09:48 ET | 200 | 1.61 |
09:50 ET | 224 | 1.605 |
09:54 ET | 800 | 1.6025 |
09:56 ET | 1000 | 1.595 |
09:57 ET | 300 | 1.61 |
10:01 ET | 300 | 1.6087 |
10:15 ET | 100 | 1.59 |
10:17 ET | 252 | 1.6 |
10:32 ET | 139 | 1.6 |
10:46 ET | 125 | 1.605 |
10:48 ET | 1967 | 1.605 |
10:51 ET | 2210 | 1.615 |
10:53 ET | 100 | 1.61 |
10:57 ET | 390 | 1.61 |
11:09 ET | 2126 | 1.6 |
11:11 ET | 1038 | 1.6 |
11:15 ET | 155 | 1.6 |
11:18 ET | 200 | 1.6 |
11:22 ET | 300 | 1.6 |
11:29 ET | 227 | 1.6 |
11:31 ET | 100 | 1.595 |
11:38 ET | 100 | 1.595 |
11:42 ET | 100 | 1.6 |
11:47 ET | 100 | 1.6025 |
11:49 ET | 327 | 1.605 |
11:54 ET | 1075 | 1.6 |
11:56 ET | 301 | 1.59 |
11:58 ET | 700 | 1.59 |
12:00 ET | 900 | 1.59 |
12:02 ET | 1328 | 1.59 |
12:05 ET | 225 | 1.585 |
12:07 ET | 227 | 1.59 |
12:12 ET | 268 | 1.5804 |
12:14 ET | 600 | 1.59 |
12:16 ET | 2049 | 1.59 |
12:20 ET | 300 | 1.585 |
12:21 ET | 100 | 1.585 |
12:23 ET | 2429 | 1.585 |
12:25 ET | 3109 | 1.58 |
12:36 ET | 672 | 1.5804 |
12:38 ET | 2141 | 1.57 |
12:39 ET | 100 | 1.5624 |
12:45 ET | 3377 | 1.55 |
12:48 ET | 2197 | 1.55 |
12:50 ET | 100 | 1.54 |
12:52 ET | 5314 | 1.54 |
12:54 ET | 125 | 1.5356 |
12:56 ET | 1000 | 1.53 |
12:57 ET | 10794 | 1.545 |
01:01 ET | 1115 | 1.54 |
01:08 ET | 1100 | 1.545 |
01:10 ET | 1520 | 1.54 |
01:12 ET | 19633 | 1.5291 |
01:14 ET | 300 | 1.53 |
01:15 ET | 1000 | 1.5266 |
01:17 ET | 1100 | 1.5293 |
01:19 ET | 200 | 1.525 |
01:21 ET | 1750 | 1.5206 |
01:24 ET | 300 | 1.525 |
01:26 ET | 460 | 1.5205 |
01:28 ET | 1211 | 1.525 |
01:33 ET | 100 | 1.5275 |
01:35 ET | 23617 | 1.52 |
01:37 ET | 5600 | 1.5 |
01:39 ET | 321 | 1.51 |
01:46 ET | 16104 | 1.5 |
01:48 ET | 466 | 1.49 |
01:50 ET | 200 | 1.49 |
01:51 ET | 200 | 1.485 |
01:53 ET | 100 | 1.4899 |
01:55 ET | 1014 | 1.49 |
02:04 ET | 200 | 1.5 |
02:06 ET | 150 | 1.4999 |
02:08 ET | 250 | 1.49 |
02:18 ET | 7666 | 1.4893 |
02:20 ET | 125 | 1.4853 |
02:22 ET | 100 | 1.485 |
02:24 ET | 400 | 1.49 |
02:27 ET | 200 | 1.49 |
02:29 ET | 1315 | 1.4999 |
02:33 ET | 200 | 1.5 |
02:36 ET | 11598 | 1.4898 |
02:45 ET | 100 | 1.48 |
02:54 ET | 380 | 1.4861 |
02:56 ET | 473 | 1.4875 |
02:58 ET | 2800 | 1.4883 |
03:02 ET | 1013 | 1.4897 |
03:03 ET | 1100 | 1.48 |
03:05 ET | 108 | 1.4889 |
03:09 ET | 3700 | 1.4899 |
03:12 ET | 1000 | 1.4899 |
03:14 ET | 2000 | 1.4892 |
03:16 ET | 100 | 1.485 |
03:18 ET | 812 | 1.49 |
03:21 ET | 300 | 1.49 |
03:25 ET | 1268 | 1.49 |
03:32 ET | 200 | 1.4811 |
03:34 ET | 100 | 1.485 |
03:38 ET | 100 | 1.485 |
03:39 ET | 420 | 1.4851 |
03:41 ET | 425 | 1.4857 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cue Biopharma Inc | 79.3M | -1.4x | --- |
Armata Pharmaceuticals Inc | 98.3M | -1.2x | --- |
BioLine RX Ltd | 58.4M | -0.9x | --- |
LAVA Therapeutics NV | 59.4M | -2.1x | --- |
Milestone Pharmaceuticals Inc | 79.9M | -1.2x | --- |
Ikena Oncology Inc | 85.4M | -1.1x | --- |
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $79.3M |
---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 48.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.99 |
EPS | $-1.07 |
Book Value | $0.79 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 11.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -732.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.